Fusion molecule based on TAA variant
AssigneeThe Regents of the University of California
InventorsZhenhua Li, Arie S. Belldegrun
Life of this patent
Estimating the term…
Abstract
This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
Claims20
A vector gene delivery system, comprising a vector that comprises a nucleic acid encoding a fusion protein comprising a portion of carbonic anhydrase IX (CAIX) variant protein (SEQ ID NO:1) attached to a granulocyte macrophage colony stimulating factor (GM-CSF), wherein the portion of the CAIX variant protein comprises the amino acids G121 and S374.
Dependencies are inferred from the claim text.